Literature DB >> 17250495

Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media.

J Antonio Serrato1, Vanessa Hernández, Sandino Estrada-Mondaca, Laura A Palomares, Octavio T Ramírez.   

Abstract

SFM (serum-free medium) is preferred to media containing animal-derived components when culturing mammalian cells for the production of therapeutic recombinant proteins and mAbs (monoclonal antibodies). Nonetheless, eliminating animal-derived components from media can strongly modify culture performance and alter protein glycosylation. In the present study, mAb glycosylation profiles, extracellular exoglycosidase activities, hybridoma growth and mAb production in traditional medium containing 10% (v/v) FBS (fetal bovine serum) [DMEM (Dulbecco's modified Eagle's medium)/FBS] were compared with those obtained in either SFM or CDM (chemically defined medium). SFM and CDM supported higher cell and mAb concentrations than did DMEM/FBS; however, CE (capillary electrophoresis) analyses revealed important changes in mAb glycosylation patterns. Glycosylation patterns showed a broad microheterogeneity in all the media, ranging from complex to high-mannose and paucimannosidic glycans. mAb produced in DMEM/FBS presented 26 glycan structures, whereas a lower glycan microheterogeneity was found for cultures in CDM or SFM, which presented 24 and 22 structures respectively. In DMEM/FBS and CDM, complex glycans without terminal galactose (G0) represented 28 and 32% of the total glycans respectively and 42 and 46% corresponded to galactosylated structures (G1 plus G2) respectively. In contrast, G0 glycans in SFM accounted for 58%, whereas only 28% corresponded to G1 and G2 structures. Extracellular beta-galactosidase activity increased approx. 3-fold in SFM, which can explain the higher G0 content compared with cultures in the other two media. A desirable decrease in sialylated structures, but an undesirable increase in fucosylated forms, was observed in mAb produced in SFM and CDM media. Approxi. 80% of potential mAb glycosylation sites were occupied, regardless of the culture medium used.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250495     DOI: 10.1042/BA20060216

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  7 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.

Authors:  Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-07       Impact factor: 3.109

3.  Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Authors:  Shui-On Leung; Kai Gao; Guang Yu Wang; Benny Ka-Wa Cheung; Kwan-Yeung Lee; Qi Zhao; Wing-Tai Cheung; Jun Zhi Wang
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Mammalian Cell Culture as a Platform for Veterinary Vaccines.

Authors:  Thailín Lao González; Ileanet Ávalos Olivera; Alina Rodríguez-Mallon
Journal:  Methods Mol Biol       Date:  2022

5.  Dynamic Modeling of CHO Cell Metabolism Using the Hybrid Cybernetic Approach With a Novel Elementary Mode Analysis Strategy.

Authors:  Juan A Martínez; Dubhe B Bulté; Martha A Contreras; Laura A Palomares; Octavio T Ramírez
Journal:  Front Bioeng Biotechnol       Date:  2020-04-15

Review 6.  Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Authors:  Leopold Grillberger; Thomas R Kreil; Sonia Nasr; Manfred Reiter
Journal:  Biotechnol J       Date:  2009-02       Impact factor: 4.677

7.  The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody.

Authors:  Ana Rita Costa; Joanne Withers; Maria Elisa Rodrigues; Niaobh McLoughlin; Mariana Henriques; Rosário Oliveira; Pauline M Rudd; Joana Azeredo
Journal:  Springerplus       Date:  2013-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.